Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biolinerx Ltd ADR (NQ: BLRX )

0.5365 -0.0035 (-0.65%)
Streaming Delayed Price Updated: 10:24 AM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biolinerx Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
BLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024
BLRX stock results show that BioLine Rx beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning! 
Via InvestorPlace
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real. 
Via InvestorPlace
BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Earnings Preview For BioLine Rx
Via Benzinga
BioLine Rx Earnings Preview
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for BioLine Rx: Here's What You Need To Know
Via Benzinga
BioLineRx Ltd. (NASDAQ: BLRX) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END 
Via FinancialNewsMedia
A Preview Of BioLine Rx's Earnings
Via Benzinga
A Preview Of BioLine Rx's Earnings
Via Benzinga
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
When you want to light your afterburners, these ideas will do the trick. 
Via InvestorPlace
Earnings Scheduled For November 20, 2023
Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million. 
Via Benzinga
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have... 
Via Talk Markets
3 Tech Stocks That Wall Street Loves More Than Nvidia
Purchase these top tech stocks now to achieve maximum profits and allow your portfolio to skyrocket given the volatile market. 
Via InvestorPlace
3 Top Penny Stocks to Make You a Millionaire in 5 Years
Penny stocks can make you a millionaire with patience and luck especially when you follow secular trends overall. 
Via InvestorPlace
BioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic Cancer
BioLineRx Ltd (NASDAQ: BLRX) announced data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination trial of motixafortide and gemcitabine and nab-paclitaxel... 
Via Benzinga
Unity Software To Rally Around 60%? Here Are 10 Other Analyst Forecasts For Friday
B of A Securities raised the price target for Unity Software Inc. (NYSE: U) from $46 to $56. B of A Securities analyst Ryan Gee upgraded the stock from Neutral to Buy. Unity Software shares fell 3% to... 
Via Benzinga
Earnings Scheduled For August 30, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its second quarter. 
Via Benzinga
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors. 
Via InvestorPlace
3 Smart Penny Stocks with Huge Potential
Find a similar success story in some of the market's top penny stocks, and you stand to make a small fortune. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023
If you dig deep enough, you’ll find some undervalued biotech stocks with substantial catalysts straight ahead. 
Via InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
NASDAQ:BLRX Long Term Shareholder Alert: Investigation of Potential Wrongdoing at BioLineRx Ltd.
San Diego, CA -- (SBWIRE) -- 04/24/2023 -- An investigation was announced for current long-term investors in shares of BioLineRx Ltd. (NASDAQ:BLRX) concerning potential breaches of fiduciary duties by... 
Via SBWire
The 3 Best Biotech Stocks Under $1 to Buy for April
While risky, here are some of the best biotech stocks under $1, with solid catalysts, investors may want to consider. 
Via InvestorPlace
Earnings Scheduled For May 24, 2023
Companies Reporting Before The Bell • Bank of Nova Scotia (NYSE:BNS) is estimated to report quarterly earnings at $1.78 per share on revenue of $8.09 billion. 
Via Benzinga
BLRX FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm – BLRX
From The Rosen Law Firm, P.A.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.